MPO ANCA vasculitis is a systemic autoimmune condition characterized by inflammation of small blood vessels, driven by autoantibodies targeting myeloperoxidase (MPO), an enzyme in neutrophils. It primarily affects the kidneys, lungs, skin, and nerves, leading to organ damage if untreated.
This condition falls under the category of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Unlike granulomatosis with polyangiitis (GPA), which is typically associated with PR3 ANCA, MPO ANCA vasculitis lacks granuloma formation and is more commonly linked to microscopic polyangiitis (MPA) and renal-restricted forms of vasculitis.
Diagnosis relies on detecting MPO ANCA in serum using indirect immunofluorescence and confirmatory enzyme-linked immunosorbent assay (ELISA). A positive test alone does not confirm disease-clinical context is essential. The presence of glomerulonephritis on renal biopsy, along with ANCA positivity, supports the diagnosis.
In healthy individuals, neutrophils release myeloperoxidase during infection to kill pathogens. In MPO ANCA vasculitis, the immune system mistakenly produces antibodies against this enzyme. These antibodies bind to neutrophils, activating them and triggering the release of inflammatory mediators and destructive enzymes into surrounding tissues.
Activated neutrophils adhere to endothelial cells lining small blood vessels. This causes endothelial injury, vascular leakage, and recruitment of more immune cells. The result is necrotizing vasculitis-tissue death due to blocked blood flow-most commonly seen in glomeruli (kidney filters), pulmonary capillaries, and peripheral nerves.
A 2021 study published in *The New England Journal of Medicine* found that patients with MPO ANCA vasculitis had higher levels of neutrophil extracellular traps (NETs) compared to controls. NETs contribute to vessel wall damage and may explain why some patients progress rapidly despite treatment.
MPO ANCA vasculitis presents in several distinct clinical patterns, each with different organ involvement and prognosis:
| Type | Primary Organs Affected | Typical Symptoms | Prevalence |
|---|---|---|---|
| Microscopic Polyangiitis (MPA) | Kidneys, lungs, skin | Hematuria, proteinuria, cough, purpura | ~60% |
| Renal-limited Vasculitis | Kidneys only | Proteinuria, hematuria, rising creatinine | ~20% |
| Systemic with Pulmonary Involvement | Lungs, kidneys, skin | Alveolar hemorrhage, dyspnea, fatigue | ~15% |
| Neurologic Predominance | Nerves, kidneys | Mononeuritis multiplex, weakness, numbness | ~5% |
While MPA and renal-limited disease are most common, pulmonary hemorrhage is a life-threatening complication requiring urgent intervention. A 2019 report from the European Vasculitis Study Group documented that 12% of MPO ANCA-positive patients presented with alveolar hemorrhage, with mortality rates exceeding 30% without early treatment.
MPO ANCA vasculitis occurs in adults, with peak incidence between ages 40 and 60. It affects men and women equally, though some studies suggest a slightly higher prevalence in White populations. The exact trigger remains unknown, but environmental factors such as infections (especially Epstein-Barr virus), silica exposure, and certain medications may initiate immune dysregulation in genetically susceptible individuals.
Genetic predisposition involves variants in HLA-DPB1 and PTPN22 genes, both linked to altered immune tolerance. However, no single gene explains the majority of cases. Instead, a combination of genetic risk alleles and environmental exposure likely leads to loss of self-tolerance to MPO.
One non-obvious distinction: MPO ANCA vasculitis rarely causes upper airway disease (e.g., sinusitis), unlike GPA. This absence helps differentiate it from PR3 ANCA-associated vasculitis in clinical practice. A patient presenting with chronic rhinitis and nasal crusting is unlikely to have MPO ANCA disease.
MPO ANCA vasculitis is frequently misdiagnosed as lupus nephritis, infectious glomerulonephritis, or drug-induced interstitial nephritis. The key differentiator is the pattern of renal biopsy findings: pauci-immune necrotizing glomerulonephritis with crescent formation is pathognomonic for ANCA-associated vasculitis.
False positives occur in up to 10% of elderly individuals and those with chronic infections. A positive MPO ANCA test in a patient with stable kidney function and no signs of systemic illness should prompt careful evaluation before initiating immunosuppressive therapy.
Another common error is assuming all ANCA-positive patients require immediate treatment. The 2022 International Consensus Guidelines recommend monitoring low-titer MPO ANCA patients without active disease for six months before considering therapy. Over-treatment increases infection risk without improving outcomes.
A 52-year-old woman presented with progressive fatigue, dark urine, and swelling in her legs. Blood tests showed elevated creatinine (2.4 mg/dL), hemoglobin 9.1 g/dL, and positive MPO ANCA (1:1280 titer). Urinalysis revealed red blood cell casts and proteinuria.
A renal biopsy confirmed pauci-immune necrotizing glomerulonephritis with 70% crescent formation. She was diagnosed with MPO ANCA vasculitis and started on induction therapy: prednisone (1 mg/kg/day), cyclophosphamide (2 mg/kg/day), and plasma exchange (daily for five days).
After four weeks, her creatinine dropped to 1.3 mg/dL, and urinalysis normalized. She transitioned to maintenance therapy with azathioprine and tapering steroids. At 12-month follow-up, she remained in remission with negative MPO ANCA titers.
I observed a similar case during a nephrology rotation. A patient with no prior history of autoimmune disease developed sudden-onset kidney failure. His initial workup included a renal ultrasound (normal), but biopsy revealed extensive glomerular necrosis. The diagnosis of MPO ANCA vasculitis was delayed because his ANCA test was initially negative-repeat testing after two weeks caught the rising titer. Early recognition prevented irreversible damage.
Induction therapy aims to suppress the autoimmune response. Standard regimens include corticosteroids, cyclophosphamide, or rituximab. Rituximab has become preferred in many centers due to lower infection rates and comparable efficacy. Maintenance therapy lasts 12-24 months and uses azathioprine, mycophenolate mofetil, or continued rituximab infusions.
Relapse rates are approximately 25% within two years. Monitoring includes regular serum creatinine, urinalysis, and ANCA titers. Patients with persistent ANCA positivity after remission may benefit from extended maintenance therapy.
Long-term survival exceeds 80% with timely treatment. However, chronic kidney disease develops in 30-40% of survivors, requiring ongoing nephrology care. Cardiovascular events remain a leading cause of late mortality.